Michael Pourdehnad

3.9k total citations · 1 hit paper
68 papers, 2.4k citations indexed

About

Michael Pourdehnad is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Michael Pourdehnad has authored 68 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Molecular Biology, 22 papers in Hematology and 20 papers in Oncology. Recurrent topics in Michael Pourdehnad's work include Protein Degradation and Inhibitors (32 papers), Multiple Myeloma Research and Treatments (18 papers) and Lymphoma Diagnosis and Treatment (18 papers). Michael Pourdehnad is often cited by papers focused on Protein Degradation and Inhibitors (32 papers), Multiple Myeloma Research and Treatments (18 papers) and Lymphoma Diagnosis and Treatment (18 papers). Michael Pourdehnad collaborates with scholars based in United States, France and Italy. Michael Pourdehnad's co-authors include Abass Alavi, Andrew B. Newberg, Eugene G. D’Aquili, Milton D. Rossman, H. Zhuang, Abass Alavi, Jill Santanna, Michael J. Baime, P. David Mozley and Steven Μ. Albelda and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Michael Pourdehnad

66 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes.

2001 506 citations H. Zhuang, Michael Pourdehnad et al. profile →

Peers

Countries citing papers authored by Michael Pourdehnad

Since Specialization

Citations

This map shows the geographic impact of Michael Pourdehnad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Pourdehnad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Pourdehnad more than expected).

Fields of papers citing papers by Michael Pourdehnad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Pourdehnad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Pourdehnad. The network helps show where Michael Pourdehnad may publish in the future.

Co-authorship network of co-authors of Michael Pourdehnad

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Pourdehnad. A scholar is included among the top collaborators of Michael Pourdehnad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Pourdehnad. Michael Pourdehnad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ABCL-1115: Golcadomide, a Cereblon E3 Ligase Modulator (CELMoD) Agent, With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Phase 1/2 Results 2025 ·Clinical Lymphoma Myeloma & Leukemia ·Emmanuel Bachy, Jean‐Marie Michot, (unknown), Judit Jørgensen, Loretta J. Nastoupil, (unknown), Guilherme Fleury Perini, (unknown), (unknown), Michael Pourdehnad, (unknown), Soraya Carrancio, (unknown), Gang Yang, (unknown)	0
2	Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) 2024 ·Blood ·Jean‐Marie Michot, Franck Morschhauser, Silvia Martina Ferrari, Judit Jørgensen, Loretta J. Nastoupil, Emmanuel Bachy, Michael Pourdehnad, (unknown), (unknown), (unknown), Soraya Carrancio, (unknown), (unknown), Julio C. Chávez	1
3	1597MO Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) 2024 ·Annals of Oncology ·(unknown), Manish R. Patel, (unknown), (unknown), (unknown), Jessica E. Hawley, S. Srinivas, (unknown), Vivek Narayan, Karie Runcie, Hamid Emamekhoo, (unknown), (unknown), Amber L. Wells, Raju Kandimalla, Satyendra Suryawanshi, Jiao Wu, Vivek Arora, Michael Pourdehnad, Amy J. Armstrong	2
4	OPEN‐LABEL PHASE 1/2 STUDY OF CC‐99282, A CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL) 2023 ·Hematological Oncology ·Jean‐Marie Michot, Julio C. Chávez, Cecilia Carpio, Emmanuel Bachy, Silvia Ferrari, Franck Morschhauser, Judit Jørgensen, Raúl Córdoba, Pierre Bories, Poliana Patah, (unknown), Soraya Carrancio, (unknown), Xin Xiao Zheng, Mei Chen, Michael Pourdehnad, Loretta J. Nastoupil	0
5	Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies 2021 ·The AAPS Journal ·R. Abbiati, Michael Pourdehnad, Soraya Carrancio, Daniel W. Pierce, Shailaja Kasibhatla, Mark McConnell, Matthew Trotter, Remco Loos, (unknown), Alexander V. Ratushny	3
6	Population Pharmacokinetics of CC-122 2021 ·Clinical Pharmacology Advances and Applications ·Yiming Cheng, Jian Chen, Michael Pourdehnad, Simon Zhou, Yan Li	3
7	Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma 2021 ·Blood ·Chad C. Bjorklund, Michael Amatangelo, Hsiling Chiu, Jian Kang, (unknown), Jessica Katz, Paulo Maciag, Patrick R. Hagner, Michael Pourdehnad, Nizar J. Bahlis, Paul G. Richardson, Anjan Thakurta	6
8	Leveraging Gene Expression Subgroups to Classify DLBCL Patients and Enrich for Clinical Benefit to a Novel Agent 2020 ·Blood ·Alberto Risueño, Patrick R. Hagner, Fadi Towfic, Celia Fontanillo, (unknown), Joel S. Parker, Clifton P. Drew, Grzegorz S. Nowakowski, Matthew J. Maurer, James R. Cerhan, Xin Wei, Yan Ren, Chung-Wein Lee, Suzana S. Couto, Maria Wang, Michael Pourdehnad, Anita K. Gandhi, Matthew Trotter	11
9	Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study 2019 ·Blood ·Geoffrey L. Uy, Mark D. Minden, Pau Montesinos, Daniel J. DeAngelo, Jessica K. Altman, (unknown), Paresh Vyas, Yngvar Fløisand, María‐Belén Vídriales, Bjørn Tore Gjertsen, Jordi Esteve, Tonia J. Buchholz, Suzana S. Couto, Jinhong Fan, Bishoy Hanna, Li Li, Daniel W. Pierce, Kristen Hege, Michael Pourdehnad, Amer M. Zeidan	23
10	A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies 2018 ·Clinical Cancer Research ·Drew Rasco, Kyriakos P. Papadopoulos, Michael Pourdehnad, Anita K. Gandhi, Patrick R. Hagner, Yan Li, Xin Wei, Rajesh Chopra, Kristen Hege, Jorge DiMartino, Kent C. Shih	74
11	CC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL) 2018 ·Annals of Oncology ·Jean‐Marie Michot, Réda Bouabdallah, Jeanette K. Doorduijn, Umberto Vitolo, Marie José Kersten, Annalisa Chiappella, Pier Luigi Zinzani, Michael Pourdehnad, Zariana Nikolova, Vincent Ribrag	4
12	CC-122, a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed and Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL) 2017 ·Blood ·Jean‐Marie Michot, Réda Bouabdallah, Jeanette K. Doorduijn, Umberto Vitolo, Marie José Kersten, Annalisa Chiappella, Pier Luigi Zinzani, (unknown), (unknown), (unknown), (unknown), Michael Pourdehnad, Kristen Hege, Li Li, Zariana Nikolova, Vincent Ribrag	3
13	Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers 2013 ·Proceedings of the National Academy of Sciences ·Michael Pourdehnad, Morgan Truitt, Imran Siddiqi, Gregory S. Ducker, Kevan M. Shokat, Davide Ruggero	204
14	PET imaging for differentiating recurrent brain tumor from radiation necrosis 2005 ·Radiologic Clinics of North America ·Roland Hustinx, Michael Pourdehnad, Bruno Kaschten, Abass Alavi	88
15	18F-FDG PET in malignant lymphoma: significance of positive findings 2005 ·European Journal of Nuclear Medicine and Molecular Imaging ·Paolo Castellucci, Pier Luigi Zinzani, Michael Pourdehnad, Lapo Alinari, Cristina Nanni, Mohsen Farsad, Giuseppe Battista, Monica Tani, Vittorio Stefoni, Romeo Canini, N Monetti, Domenico Rubello, Abass Alavi, Roberto Franchi, Stefano Fanti	51
16	Extensive Distribution of Liposomes in Rodent Brains and Brain Tumors Following Convection-Enhanced Delivery 2004 ·Journal of Neuro-Oncology ·Christoph Mamot, John Nguyen, Michael Pourdehnad, Piotr Hadaczek, Ryuta Saito, John R. Bringas, Daryl C. Drummond, Keelung Hong, Dmitri B. Kirpotin, Tracy R. McKnight, Mitchel S. Berger, John W. Park, Krys S. Bankiewicz	110
17	Do high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders? 2001 ·Nuclear Medicine Communications ·H. Zhuang, (unknown), Michael Pourdehnad, L.-E. Adam, (unknown), R Martínez-Lázaro, (unknown), (unknown), Milton D. Rossman, Abass Alavi	79
18	Intense F-18 fluorodeoxyglucose uptake caused by mycobacterium avium intracellulare infection. 2001 ·Clinical Nuclear Medicine ·(unknown), Michael Pourdehnad, Alvin J. Yamamoto, Milton D. Rossman, Abass Alavi	19
19	Gastric emptying of solids: Estimates of lag phase and constant emptying times 2000 ·Nuclear Medicine Communications ·Olivier Couturier, (unknown), (unknown), Michael Pourdehnad, B. Bridji, A. Turzo, Y. Bizais	13
20	Adverse effects of edema on adjacent gray matter function in patients with brain tumor as determined by FDG-PET imaging. 1999 ·Open Repository and Bibliography (University of Liège) ·Michael Pourdehnad, Paulo Schiavom Duarte, (unknown), Roland Hustinx, Abass Alavi	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact